Tata Chemicals (TATACHEM) Q3 24/25 earnings summary

Executive summary

• Revenue declined 4% year-over-year in Q3 FY25, mainly due to pricing pressure and adverse price movements, despite record production volumes in India and the U.S.

• Asian markets, especially China and India, showed robust volume growth, while U.S. and Western Europe experienced reduced demand, particularly in glass sectors.

• The Lostock soda ash plant in the U.K. ceased operations due to sustained underperformance, with an exceptional charge of INR 70 crores/₹70 crore for decommissioning and employee benefits.

• Inventory levels increased due to timing issues in U.S. shipments and full-capacity production testing in India.

• Strategic focus remains on capacity expansion, sustainability, and value-added products across geographies.

Financial highlights

• Q3FY25 consolidated revenue at ₹3,590 crore, down 4% year-over-year; EBITDA at ₹434 crore, down 20%; PAT at ₹49 crore, down 75%.

• Consolidated Q3 net loss: ₹53 crore, compared to net profit of ₹194 crore in Q2 and ₹158 crore in Q3 FY23.

• Net debt increased to ₹6,722 crore as of Dec 2024, up from ₹5,329 crore in Sep 2024 and ₹4,377 crore in Dec 2023.

• EBITDA for India business in Q3 was INR 209 crores, up from INR 144 crores in the previous quarter and nearly flat year-over-year.

• U.S. sales volumes increased, but prices were lower than Q3 FY24; maintenance shutdowns led to a cost impact of about INR 30 crores.

Outlook and guidance

• Pricing is expected to remain at current levels or trend slightly lower for the next three to six months.

• Sales volumes in India and U.S. are expected to remain strong in Q4, with India able to place more material in the market.

• CapEx plans remain, but expansions in U.S. and Kenya will be phased to match cash flows and market conditions.

• Ongoing cessation of non-profitable UK soda ash operations; continued capex and working capital investments.

• Management expects current unsustainable price levels, especially in China, to eventually correct.